BMT Autologous MSCs for GvHD

Key facts

Sponsor

Emory University

Principal Investigator

Muna Qayed, MD

Children's Healthcare of Atlanta/Emory University

Intervention

Autologous mesenchymal stromal cells (MSCs)(biological)

Enrollment

11 enrolled

Eligibility

12 years · All sexes

Timeline

2015 – 2021

Study locations (1)

• Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States

Collaborators

CURE Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare disorder potentially indicated for transplant or complication after transplantation

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT04886726
  PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
  Henry Ford Health System
• RECRUITINGPHASE2, PHASE3NCT03818334
  Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
  Hospital Israelita Albert Einstein

See all trials for Rare disorder potentially indicated for transplant or complication after transplantation →